• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Patricia Coyle: Ofatumumab Has the Benefit of Being Taken at Home

Video

The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.

Ofatumumab was recently approved to treat relapsing forms of multiple sclerosis (MS), making it a direct competitor of ocrelizumab; the biggest difference between the 2 therapies is that ofatumumab can be taken at home, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.

Transcript

Ofatumumab was recently approved for relapsing forms of multiple sclerosis. How does it fit into the treatment landscape for patients with MS?

Ofatumumab is a human anti-CD20. As an MS anti-CD20, it is a high-efficacy monoclonal agent. It will be a direct competitor for ocrelizumab, the humanized anti-CD20. Probably the biggest difference is that ofatumumab is given by a subcutaneous monthly injection every 4 weeks and can be delivered at home. This is after a 20 milligram, 3 times over 2 weeks loading dose, and then it's 20 milligrams [subcutaneously] every 4 weeks. That's in contrast to ocrelizumab, which is given intravenously every 6 months.

So, I think you have now a choice between 2 anti-CD20s that are high-efficacy, relatively safe options. One you come to an infusion center twice a year, the other you inject at home subcutaneously monthly.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.